Shopping Cart 0
Cart Subtotal
USD 0

Alligator Bioscience AB (ATORX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Alligator Bioscience AB (Alligator Bioscience) is a clinical-stage biotechnology company that discovers and develops antibody based pharmaceuticals for the treatment of cancer. The company's pipeline products include ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527. The ADC-1013, currently under phase 1 clinical study, is a human, monospecific, agonistic, IgG1 antibody used for immunotherapy of cancer. The ATOR-1015, currently under second phase of production, is a bispecific immune activating antibody intended for tumor-directed immunotherapy. Its preclinical development phase products ATOR-1017 and ALG.APV-527 are antibodies for activating the co-stimulatory receptor 4-1BB, and for treating tumor-directed immunotherapy respectively. The company develops immunotherapies such as agonistic mono- and bispecific antibodies. It develops immunotherapeutic product candidates using proprietary technologies, Alligator-Gold and fragment induced diversity (FIND). Alligator Bioscience is headquartered in Lund, Sweden.

Alligator Bioscience AB (ATORX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alligator Bioscience AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Alligator Bioscience to Raise Funds through Venture Financing 12

Alligator Bioscience Raises USD3 Million in Venture Financing 13

Partnerships 14

Alligator Bioscience Enters into Agreement with Center for Applied Medical and Clinica Universidad 14

Alligator Bioscience Expands Agreement with Stanford University 15

Aptevo Therapeutics and Alligator Bioscience Enter into Co-Development Agreement 16

BioInvent International Enters into Agreement with Alligator Bioscience 17

Cobra Biologics Enters into Contract with Alligator Bioscience 18

Clinical Laserthermia Systems Signs Agreement with Alligator Bioscience 19

Alligator Bioscience Enters Into Research Agreement With Sweden Biotech Company 20

Licensing Agreements 21

Janssen Biotech Enters into Licensing Agreement with Alligator Bioscience for ADC-1013 21

Equity Offering 22

Alligator Bioscience Raises USD252.8 Million in IPO 22

Alligator Bioscience Raises Funds in Private Placement 24

Acquisition 25

Alligator Bioscience Acquires Atlas Therapeutics 25

Alligator Bioscience AB-Key Competitors 26

Alligator Bioscience AB-Key Employees 27

Alligator Bioscience AB-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Jul 12, 2018: Alligator Bioscience: Interim Report January-June 2018 29

Apr 26, 2018: Alligator Bioscience Interim Report January-March 2018 30

Feb 16, 2018: Alligator Bioscience Full Year Report 2017 31

Oct 25, 2017: Alligator Bioscience: Interim Report January-September 2017 32

Aug 23, 2017: Alligator Bioscience: Interim Report January-June 2017 33

May 02, 2017: Alligator Bioscience Interim report January-March 2017 34

Feb 17, 2017: Alligator Bioscience Full Year 2016 Report 35

Corporate Communications 36

Dec 04, 2017: Alligator Bioscience expands management team 36

Product News 37

10/24/2017: Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527 37

10/24/2017: Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527-a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics 38

Clinical Trials 39

Jul 19, 2018: Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody 39

May 08, 2018: New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 presented by Alligator Bioscience and Aptevo Therapeutics 40

Apr 17, 2018: Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation 41

Jan 25, 2018: Alligator Bioscience contracts Theradex Oncology as clinical CRO for the forthcoming Phase I study with ATOR-1015 42

Aug 17, 2017: Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527 43

Jun 12, 2017: Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 to pre-clinical development 44

May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference;-Strong new preclinical findings for ATOR-1015 45

Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alligator Bioscience AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alligator Bioscience AB, Deals By Therapy Area, 2012 to YTD 2018 9

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Alligator Bioscience to Raise Funds through Venture Financing 12

Alligator Bioscience Raises USD3 Million in Venture Financing 13

Alligator Bioscience Enters into Agreement with Center for Applied Medical and Clinica Universidad 14

Alligator Bioscience Expands Agreement with Stanford University 15

Aptevo Therapeutics and Alligator Bioscience Enter into Co-Development Agreement 16

BioInvent International Enters into Agreement with Alligator Bioscience 17

Cobra Biologics Enters into Contract with Alligator Bioscience 18

Clinical Laserthermia Systems Signs Agreement with Alligator Bioscience 19

Alligator Bioscience Enters Into Research Agreement With Sweden Biotech Company 20

Janssen Biotech Enters into Licensing Agreement with Alligator Bioscience for ADC-1013 21

Alligator Bioscience Raises USD252.8 Million in IPO 22

Alligator Bioscience Raises Funds in Private Placement 24

Alligator Bioscience Acquires Atlas Therapeutics 25

Alligator Bioscience AB, Key Competitors 26

Alligator Bioscience AB, Key Employees 27

Alligator Bioscience AB, Subsidiaries 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Alligator Bioscience AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Alligator Bioscience AB (Alligator Bioscience) is a clinical-stage biotechnology company that discovers and develops antibody based pharmaceuticals for the treatment of cancer. The company's pipeline products include ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527. The ADC-1013, currently under phase 1 clinical study, is a human, monospecific, agonistic, IgG1 antibody used for immunotherapy of cancer. The ATOR-1015, currently under second phase of production, is a bispecific immune activating antibody intended for tumor-directed immunotherapy. Its preclinical development phase products ATOR-1017 and ALG.APV-527 are antibodies for activating the co-stimulatory receptor 4-1BB, and for treating tumor-directed immunotherapy respectively. The company develops immunotherapies such as agonistic mono- and bispecific antibodies. It develops immunotherapeutic product candidates using proprietary technologies, Alligator-Gold and fragment induced diversity (FIND). Alligator Bioscience is headquartered in Lund, Sweden.

Alligator Bioscience AB (ATORX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alligator Bioscience AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Alligator Bioscience to Raise Funds through Venture Financing 12

Alligator Bioscience Raises USD3 Million in Venture Financing 13

Partnerships 14

Alligator Bioscience Enters into Agreement with Center for Applied Medical and Clinica Universidad 14

Alligator Bioscience Expands Agreement with Stanford University 15

Aptevo Therapeutics and Alligator Bioscience Enter into Co-Development Agreement 16

BioInvent International Enters into Agreement with Alligator Bioscience 17

Cobra Biologics Enters into Contract with Alligator Bioscience 18

Clinical Laserthermia Systems Signs Agreement with Alligator Bioscience 19

Alligator Bioscience Enters Into Research Agreement With Sweden Biotech Company 20

Licensing Agreements 21

Janssen Biotech Enters into Licensing Agreement with Alligator Bioscience for ADC-1013 21

Equity Offering 22

Alligator Bioscience Raises USD252.8 Million in IPO 22

Alligator Bioscience Raises Funds in Private Placement 24

Acquisition 25

Alligator Bioscience Acquires Atlas Therapeutics 25

Alligator Bioscience AB-Key Competitors 26

Alligator Bioscience AB-Key Employees 27

Alligator Bioscience AB-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Jul 12, 2018: Alligator Bioscience: Interim Report January-June 2018 29

Apr 26, 2018: Alligator Bioscience Interim Report January-March 2018 30

Feb 16, 2018: Alligator Bioscience Full Year Report 2017 31

Oct 25, 2017: Alligator Bioscience: Interim Report January-September 2017 32

Aug 23, 2017: Alligator Bioscience: Interim Report January-June 2017 33

May 02, 2017: Alligator Bioscience Interim report January-March 2017 34

Feb 17, 2017: Alligator Bioscience Full Year 2016 Report 35

Corporate Communications 36

Dec 04, 2017: Alligator Bioscience expands management team 36

Product News 37

10/24/2017: Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527 37

10/24/2017: Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527-a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics 38

Clinical Trials 39

Jul 19, 2018: Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody 39

May 08, 2018: New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 presented by Alligator Bioscience and Aptevo Therapeutics 40

Apr 17, 2018: Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation 41

Jan 25, 2018: Alligator Bioscience contracts Theradex Oncology as clinical CRO for the forthcoming Phase I study with ATOR-1015 42

Aug 17, 2017: Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527 43

Jun 12, 2017: Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 to pre-clinical development 44

May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference;-Strong new preclinical findings for ATOR-1015 45

Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alligator Bioscience AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alligator Bioscience AB, Deals By Therapy Area, 2012 to YTD 2018 9

Alligator Bioscience AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Alligator Bioscience to Raise Funds through Venture Financing 12

Alligator Bioscience Raises USD3 Million in Venture Financing 13

Alligator Bioscience Enters into Agreement with Center for Applied Medical and Clinica Universidad 14

Alligator Bioscience Expands Agreement with Stanford University 15

Aptevo Therapeutics and Alligator Bioscience Enter into Co-Development Agreement 16

BioInvent International Enters into Agreement with Alligator Bioscience 17

Cobra Biologics Enters into Contract with Alligator Bioscience 18

Clinical Laserthermia Systems Signs Agreement with Alligator Bioscience 19

Alligator Bioscience Enters Into Research Agreement With Sweden Biotech Company 20

Janssen Biotech Enters into Licensing Agreement with Alligator Bioscience for ADC-1013 21

Alligator Bioscience Raises USD252.8 Million in IPO 22

Alligator Bioscience Raises Funds in Private Placement 24

Alligator Bioscience Acquires Atlas Therapeutics 25

Alligator Bioscience AB, Key Competitors 26

Alligator Bioscience AB, Key Employees 27

Alligator Bioscience AB, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Alligator Bioscience AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.